ACALABRUTINIB MONOTHERAPY AND IMPACT OF AUTOIMMUNE CYTOPENIAS IN A SERIES OF PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA (SIE 2026) - Oct 6, 2026 - Abstract #DP134; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "Almost all patients with pre-existing AIC (95%) re- ceived AIC-directed therapy, specifically corticosteroids (35%) as monotherapy or combined with rituximab (25%). Conclusions. In this multicenter real-world study, pre-exist- ing AICs were generally manageable in CLL patients treated with acalabrutinib; treatment-emergent AICs were infre- quent and controllable, and overall AICs did not adversely impact clinical outcomes."
Clinical • Monotherapy • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia
|
|
A. Ferrario1; G. Zamprogna1; B. Bianchi1; F. Perutelli2; G. Camagni1,3; L. Bertù3; I. Innocenti4; V. Oggianu5; A. Cellini6; M. Merli7; R. Moia8; F. Martini9; A. Galitzia10; E. Boccellato11; F. De Falco12; M. Deodato13; E. A. Martino14; M. Gentile14; A. M. Frustaci13; P. Sportoletti12; L. Scarfò9,15; G. Gaidano8; C. Vitale2; A. Visentin6; R. Murru5; L. Laurenti4; M. Coscia1,3
|